Holen Sie sich die Stockscreener-App
8.40
7.28%
0.57
Handel nachbörslich:
8.30
-0.10
-1.19%
Schlusskurs vom Vortag:
$7.83
Offen:
$7.83
24-Stunden-Volumen:
29,387
Relative Volume:
0.18
Marktkapitalisierung:
$5.20M
Einnahmen:
$644.60K
Nettoeinkommen (Verlust:
$-9.87M
KGV:
-0.01
EPS:
-837.9618
Netto-Cashflow:
$-9.02M
1W Leistung:
+1.45%
1M Leistung:
+39.53%
6M Leistung:
-49.09%
1J Leistung:
-83.94%
1-Tages-Spanne:
$7.50
$8.40
1-Wochen-Bereich:
$7.0001
$11.88
52-Wochen-Spanne:
$5.0001
$108.90
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Firmenname
Biodexa Pharmaceuticals Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
8.40 | 4.85M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-08 | Eingeleitet | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Aktie (BDRX) Neueste Nachrichten
Why Did Biodexa Pharmaceuticals' Stock Drop After-Hours Despite Big Gain During Regular Trading? - inkl
Biodexa Hosts Breakfast Symposium on FAP Mechanisms and Chemoprevention at CGA‑IGC in October 2025 - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Decreases By 53.3% - Defense World
Interim results for the six months ended June 30, 2025 - GlobeNewswire
Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year - TipRanks
Biodexa says requirement for financing represents ‘material uncertainty’ - TipRanks
First Patients Enrolled: Biodexa's Breakthrough FAP Treatment Advances to Pivotal Phase 3 Trial with $35M Backing - Stock Titan
Biodexa begins phase 3 trial of FAP treatment with $20M funding By Investing.com - Investing.com South Africa
Biodexa begins phase 3 trial of FAP treatment with $20M funding - Investing.com Canada
$7 Billion Untapped Market: Biodexa's eRapa Could Be First FDA-Approved Drug for Devastating FAP Disease - Stock Titan
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled - The Globe and Mail
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Biodexa announces enrollment of first two patients in Phase 3 Serenta trial - MSN
Biodexa Pharmaceuticals (NASDAQ:BDRX) Trading 2.3% Higher – Time to Buy? - Defense World
Biodexa Announces Enrolment of First Patients into Pivotal - GlobeNewswire
[6-K] Biodexa Pharmaceuticals plc American Depositary Shs Current Report (Foreign Issuer) - Stock Titan
$7.3 Billion Market Opportunity: Biodexa's eRapa Could Become First-Ever Drug Treatment for FAP Cancer Risk - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Cut to Strong Sell at Wall Street Zen - Defense World
Biodexa completes ADR ratio change to 1:100,000 ordinary shares By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals Implements ADR Ratio Change - TipRanks
ADR Ratio Change Effective | BDRX Stock News - GuruFocus
Biodexa completes ADR ratio change to 1:100,000 ordinary shares - Investing.com
Biodexa Pharmaceuticals PLC ADR ratio changes to 1:100,000. - AInvest
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - AInvest
ADR Ratio Change Effective - GlobeNewswire
Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active - Stock Titan
Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com Nigeria
Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan
Biodexa advances FAP treatment with phase 3 trial initiation - Investing.com
Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest
MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest
ADR Ratio Change - GlobeNewswire
Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan
Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India
Biodexa files European clinical trial application for FAP treatment - Investing.com
Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan
SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com
Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com
Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan
Biodexa Announces Activation of First Clinical Study Site - GlobeNewswire
Biodexa Unveils Phase 3 FAP Trial "Serenta": New Hope for Rare Disease Patients - Stock Titan
Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com
Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan
Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals changes share nominal value - Investing.com
Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India
Finanzdaten der Biodexa Pharmaceuticals Plc Adr-Aktie (BDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):